Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06426758
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-19
Brief Title:
Graves Disease Induced by Epstein-Barr Virus Lytic Reactivation
Sponsor:
Xiao-Ming Mao
Organization:
Nanjing Medical University
Study Overview
Official Title:
The Morbidity of Graves Disease and Recurrence Rate of Hyperthyroidism Due to Epstein-Barr Virus Lytic Reactivation
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Previous studies have proved that the lytic reactivation of latent Epstein-Barr virus EBV was significantly associated with the onset of Gravesdisease GD however the morbidity of GD and recurrence rate of hyperthyroidism after antithyroid drugs treatment due to lytic reactivation of EBV is not understood We will recruit patients with newly diagnosed GD and recurrence of hyperthyroidism after antithyroid drugs treatment In order to confirm lytic reactivation of EBV the number of EBV DNA copiesmRNA and protein expression of immediate-early early and late lytic EBV genesEBV TRAbcells will be tested The proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism was evaluated
Detailed Description:
The lytic reactivation of latent EBV play importment roles in development of GD and recurrence rate of hyperthyroidism The aim of this study is to evaluate the proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism
All patients satisfied the diagnostic criteria for GD The diagnotic remission of hyperthyroidism was included of clinical symptoms and elevated FT3 and FT4 the patients who have been received antithyroid drugs methimazole or propylthiouracil titration treatment for 18 or more months and of antithyroid drugs titration treatment and withdrawal antithyroid drugs at least 3 months
The evaluation of lytic reactivation of latent EBV including EBV DNA copiesmRNA and protein expression of immediate-early early and late lytic genesand EBV TRAbcells The EBV DNA copies was tested with PCR mRNA and protein expression of immediate-early early and late lytic EBV genes were analysed with RT-qPCR or Western blot and EBV TRAbcells were evaluated with flow cytometry
All statistical tests were performed using GraphPad Prism V80
All patients satisfied the diagnostic criteria for GD The diagnotic remission of hyperthyroidism was included of clinical symptoms and elevated FT3 and FT4 the patients who have been received antithyroid drugs methimazole or propylthiouracil titration treatment for 18 or more months and of antithyroid drugs titration treatment and withdrawal antithyroid drugs at least 3 months
The evaluation of lytic reactivation of latent EBV including EBV DNA copiesmRNA and protein expression of immediate-early early and late lytic genesand EBV TRAbcells The EBV DNA copies was tested with PCR mRNA and protein expression of immediate-early early and late lytic EBV genes were analysed with RT-qPCR or Western blot and EBV TRAbcells were evaluated with flow cytometry
All statistical tests were performed using GraphPad Prism V80
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None